

Leqselvi (deuruxilitinib)
Effective 12/01/2025

| | | | | |
|------------------------------|--|--|--|--|
| Plan | <input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange | | Program Type | <input checked="" type="checkbox"/> Prior Authorization |
| Benefit | <input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit | | | <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy |
| Specialty Limitations | This medication has been designated specialty and must be filled at a contracted specialty pharmacy. | | | |
| Contact Information | Medical Benefit Pharmacy Benefit | | Phone: 833-895-2611 Phone: 800-711-4555 | Fax: 888-656-6671 Fax: 844-403-1029 |
| Exceptions | N/A | | | |

Overview

Leqselvi (deuruxilitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata.

Leqselvi is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all the following criteria are met:

1. Member is 18 years of age or older
2. Diagnosis of severe alopecia areata
3. Member has at least 50% scalp hair loss (e.g., Severity of Alopecia Tool (SALT) score of 50 or higher)
4. Other forms of alopecia have been ruled out (e.g., androgenetic alopecia, trichotillomania, telogen effluvium, chemotherapy-induced hair loss, tinea capitis)
5. Trial and failure, contraindication, or intolerance to one of the following:
 - a. Litfulo (ritlecitinib)
 - b. Olumiant (baricitinib)

Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

1. Documentation is submitted supporting improvement in signs and symptoms of alopecia areata from baseline (e.g., increased hair on scalp, eyebrows, eyelashes)

Limitations

1. Initial approvals will be granted for 36 weeks
2. Reauthorizations will be granted for 12 months
3. The following quantity limits apply:

| Drug Name and Dosage Form | Quantity Limit |
|---------------------------|----------------|
|---------------------------|----------------|

| | |
|-----------------|-------------------|
| Leqselvi tablet | 2 tablets per day |
|-----------------|-------------------|

References

1. Alopecia Areata. National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS]. <https://www.niams.nih.gov/health-topics/alopecia-areata>. Updated August 2024. Accessed October 7, 2024.
2. Eisman S, Sinclair R. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata. *Expert Opin Investig Drugs*. 2021;30(12):1169-1174.
3. Gilhar A, Etzioni A, Paus R. Alopecia areata. *N Engl J Med*. 2012;366(16):1515-1525.
4. Gupta AK, Wang T, Polla Ravi S, et al. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors. *J Eur Acad Dermatol Venereol*. 2023;37(4):666-679.
5. King B, Senna MM, Mesinkovska NA, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the phase 3 randomized, controlled trial (THRIVE-AA1). *J Am Acad Dermatol*. 2024 Jul 23:S0190-9622(24)02550-7.
6. Leqselvi [package insert], Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2024.
7. Liu M, Gao Y, Yuan Y, et al. Janus kinase inhibitors for alopecia areata: a systematic review and meta-analysis. *JAMA Netw Open*. 2023;6(6):e2320351.
8. Meah N, Wall D, York K, et al. The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata. *J Am Acad Dermatol*. 2020;83(1):123-130.
9. Mostaghimi A, Gao W, Ray M, et al. Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a US employer-sponsored insured population. *JAMA Dermatol*. 2023;159(4):411-418.
10. National Alopecia Areata Foundation. Related conditions. <https://www.naaf.org/alopecia-areata/related-conditions/>. 2024. Accessed October 7, 2024.
11. Ramírez-Marín HA, Tosti A. Evaluating the therapeutic potential of ritlecitinib for the treatment of alopecia areata. *Drug Des Devel Ther*. 2022;16:363-374.

Review History

09/10/2025 – Created and reviewed at September P&T. Effective 12/1/2025.

